Keros Therapeutics (KROS) Expected to Post Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Keros Therapeutics to announce earnings of ($1.25) per share and revenue of $0.8070 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $10.07 on Wednesday. The stock has a market capitalization of $199.29 million, a P/E ratio of -3.35 and a beta of 0.97. Keros Therapeutics has a 52-week low of $9.69 and a 52-week high of $22.55. The stock’s 50-day simple moving average is $10.77 and its 200 day simple moving average is $12.84.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KROS. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.40.

Insider Activity at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director directly owned 10,958 shares in the company, valued at $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director owned 9,767 shares in the company, valued at $104,702.24. This represents a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,425 shares of company stock valued at $89,994. Company insiders own 12.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its position in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the last quarter. New York State Common Retirement Fund boosted its stake in Keros Therapeutics by 264.1% in the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in Keros Therapeutics during the third quarter valued at approximately $176,000. Finally, XTX Topco Ltd bought a new position in Keros Therapeutics during the fourth quarter valued at approximately $212,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.